Jonathan D.J. Loeb Ph.D.

jonathan-loeb

Jonathan D.J. Loeb Ph.D.

Partner

Silicon Valley | 2440 W. El Camino Real, Suite 700, Mountain View, CA 94040-1499
+1 650 813 4995 | +1 650 813 4848

| vCard | PDF

Jonathan D.J. Loeb, Ph.D.’s practice focuses on life sciences litigation and strategic patent counseling. To achieve his clients’ strategic goals, Dr. Loeb melds the technical expertise gained in more than 10 years as a bench scientist and teacher with his deep experience in all aspects of high-stakes biotech, pharmaceutical, and medical device patent litigation. Recently, he was named a "Life Sciences Star" in LMG Life Sciences 2017.

Dr. Loeb has represented clients before U.S. District Courts, the International Trade Commission, and the Federal Circuit Court of Appeals. Dr. Loeb also represents clients in reexamination proceedings before the U.S. Patent Office, and has provided advice in patent revocation and infringement actions in various foreign jurisdictions.

Before attending Stanford Law School, Dr. Loeb obtained his Ph.D. in Biology from the Massachusetts Institute of Technology. At M.I.T., Dr. Loeb worked at the Whitehead Institute for Biomedical Research with its then director, Professor Gerald R. Fink. Dr. Loeb’s doctoral research concerned the genetics and cell biology of the Nuclear Pore Complex in Saccharomyces cerevisiae. After receiving his Ph.D., Dr. Loeb did post-doctoral research at M.I.T. and the University of California, Irvine, focusing on the pathogenesis of fungi that afflict immunocompromised individuals. Dr. Loeb is lead author of a number of scientific papers in peer-reviewed biology journals.

Experience
  • Endo Pharmaceuticals Inc. vs. Teva Pharmaceuticals USA, Inc., et al. (U.S. Dist. Ct. Del.). Trial counsel representing Endo in a Hatch-Waxman patent infringement case regarding Endo’s Opana® ER controlled release oxymorphone product against seven generic pharmaceutical manufacturers. Obtained verdict of infringement and validity. Currently representing Endo on appeal.  
  • Endo Pharmaceuticals Inc. vs. Teva Pharmaceuticals USA, Inc., et al. (U.S. Dist. Ct. S. N.Y.). Trial counsel representing Endo in a Hatch-Waxman patent infringement case regarding Endo’s Opana® ER controlled-release oxymorphone product against nine generic pharmaceutical manufacturers. Obtained verdict of infringement and validity. Currently representing Endo on appeal.
  • Endo Pharmaceuticals Inc. vs. Watson Pharmaceuticals, Inc., et al. (U.S. Dist. Ct. S. N.Y.). Trial counsel representing Endo in a Hatch-Waxman patent infringement case regarding Endo’s Lidoderm® lidocaine patch product against generic pharmaceutical manufacturers. Settled favorably after trial.
  • Amgen Inc. v. F. Hoffman LaRoche, Ltd. (U.S. Dist. Ct. Mass.). Served as a member of the Senior Trial Team representing Amgen in a patent infringement case regarding recombinant erythropoietin. Obtained a jury verdict of infringement and validity.
  • In the Matter of Certain Products and Pharmaceutical Compositions Containing Recombinant Human Erythropoietin (U.S. International Trade Commission) Trial counsel for Amgen in ITC investigation regarding the exclusion from importation into the U.S. of Roche’s Mircera® product (appeal in Amgen’s favor, settled favorably).
  • Pfizer Inc v. Lilly ICOS (U.S. Dist. Ct. Del.). Defended Lilly ICOS in a patent dispute regarding phosphodiesterase-5 inhibitors Cialis® and Viagra®. Obtained stay after successful petition for reexamination.
  • Boston Scientific v. Cook (U.S. Dist. Court Ill. and Seventh Cir.) Counsel for Angiotech in dispute between licensees regarding license rights to paclitaxel stents (favorably resolved).
  • Amgen Inc. v. Hoechst Marion Roussel, Inc. (U.S. Dist. Ct. Mass.) Represented Amgen in this patent dispute, obtaining holdings of infringement and validity in two bench trials as well as numerous appeals.
  • Biogen v. Amgen (U.S. Dist. Ct. Mass.) Represented Amgen in infringement action involving Amgen’s recombinant granulocyte colony stimulating factor product (Neupogen®) (summary judgment in Amgen’s favor).
Education
  • University of California, Berkeley, A.B., Molecular Biology, 1987, High Honors, recipient of the Departmental Citation (awarded to top student in department), National Merit Scholar
  • Massachusetts Institute of Technology (MIT), Ph.D., Biology, 1995
  • Stanford Law School, J.D., 2000
Admissions
  • California
  • United States Court of Appeals for the Federal Circuit
  • United States Patent and Trademark Office
  • United States District Court for the Northern District of California